Active, not recruitingPhase 2NCT05540327
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Principal Investigator
- Medical ResponsibleMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Intervention
- M5049 low dose(drug)
- Enrollment
- 379 enrolled
- Eligibility
- 18-76 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States
- Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
- Advance Medical Research Center, Miami, Florida, United States
- Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States
- AA MRC LLC Ahmed Arif Medical Research Center, Grand Blanc, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Ohio State University - CTMO Parent, Columbus, Ohio, United States
- Ramesh C Gupta, MD, Memphis, Tennessee, United States
- Centro de Investigaciones Medicas Mar del Plata - CIM, Buenos Aires, Argentina
- CINME - Centro De Investigaciones Metabolicas, Buenos Aires, Argentina
- Buenos Aires Skin, Ciudad Autonoma Buenos Aires, Argentina
- Hospital Militar Central Dr. Cosme Argerich, Ciudad Autonoma Buenos Aires, Argentina
- Centro de Investigaciones Medicas Mar del Plata - CIM, Mar del Plata, Argentina
- Instituto de Reumatologia, Mendoza, Argentina
- Instituto Medico de alta Complejidad San Isidro S.A (IMAC), San Fernando, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05540327 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology